IL17A and psoriasis: In support of this, CAP significantly reduced inflammatory cytokines such as IL‐17A, IL‐23A, IL‐24, IL‐1β, and TNFα in psoriasis cells and modulated critical factors in the MAPK pathway in vitro, and led to substantial improvements in factors such as skin thickness, erythema and scaling in vivo [241].